Envestnet Portfolio Solutions Inc. Sells 2,994 Shares of Humana Inc. (NYSE:HUM)

Envestnet Portfolio Solutions Inc. trimmed its stake in shares of Humana Inc. (NYSE:HUM - Free Report) by 56.7% in the first quarter, according to the company in its most recent filing with the SEC. The firm owned 2,289 shares of the insurance provider's stock after selling 2,994 shares during the quarter. Envestnet Portfolio Solutions Inc.'s holdings in Humana were worth $606,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Revolve Wealth Partners LLC bought a new position in Humana in the fourth quarter valued at about $202,000. Truist Financial Corp boosted its stake in shares of Humana by 15.6% during the fourth quarter. Truist Financial Corp now owns 8,865 shares of the insurance provider's stock valued at $2,249,000 after purchasing an additional 1,199 shares in the last quarter. D.A. Davidson & CO. boosted its stake in shares of Humana by 19.0% during the fourth quarter. D.A. Davidson & CO. now owns 1,283 shares of the insurance provider's stock valued at $326,000 after purchasing an additional 205 shares in the last quarter. Atria Wealth Solutions Inc. boosted its stake in shares of Humana by 21.1% during the fourth quarter. Atria Wealth Solutions Inc. now owns 1,610 shares of the insurance provider's stock valued at $409,000 after purchasing an additional 281 shares in the last quarter. Finally, Sigma Planning Corp boosted its stake in shares of Humana by 122.0% during the fourth quarter. Sigma Planning Corp now owns 1,456 shares of the insurance provider's stock valued at $369,000 after purchasing an additional 800 shares in the last quarter. 92.38% of the stock is currently owned by institutional investors.

Humana Trading Up 0.7%

Shares of HUM stock opened at $240.24 on Friday. The company has a market cap of $28.99 billion, a P/E ratio of 16.99, a PEG ratio of 1.80 and a beta of 0.43. The stock has a 50 day simple moving average of $242.39 and a two-hundred day simple moving average of $259.73. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.91 and a current ratio of 1.91. Humana Inc. has a fifty-two week low of $212.45 and a fifty-two week high of $406.46.

Humana (NYSE:HUM - Get Free Report) last issued its earnings results on Wednesday, April 30th. The insurance provider reported $11.58 earnings per share for the quarter, topping analysts' consensus estimates of $10.07 by $1.51. The business had revenue of $32.11 billion during the quarter, compared to the consensus estimate of $32 billion. Humana had a return on equity of 14.47% and a net margin of 1.42%. The firm's revenue for the quarter was up 8.4% on a year-over-year basis. During the same period in the previous year, the company posted $7.23 earnings per share. Research analysts forecast that Humana Inc. will post 16.47 earnings per share for the current year.

Humana Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, July 25th. Stockholders of record on Friday, June 27th will be given a dividend of $0.885 per share. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.47%. The ex-dividend date of this dividend is Friday, June 27th. Humana's payout ratio is 25.04%.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on HUM. Mizuho lifted their price target on Humana from $305.00 to $316.00 and gave the company an "outperform" rating in a research note on Wednesday, April 9th. Oppenheimer lifted their price target on Humana from $300.00 to $310.00 and gave the company an "outperform" rating in a research note on Thursday, May 1st. Bank of America cut their price target on Humana from $320.00 to $260.00 and set a "neutral" rating on the stock in a research note on Tuesday, June 17th. Wall Street Zen lowered Humana from a "buy" rating to a "hold" rating in a research note on Saturday, June 14th. Finally, Barclays set a $268.00 price objective on Humana and gave the stock an "equal weight" rating in a research note on Thursday, June 12th. Seventeen research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Hold" and a consensus price target of $280.76.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.